Market Closed - Nasdaq 04:00:00 2023-11-28 pm EST Intraday chart for Hologic, Inc. 5-day change 1st Jan Change
69.87 USD -2.32% -2.84% -6.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Hologic, Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-28-2023 02:10 PM CI
UBS Cuts Price Target on Hologic to $78 From $91, Maintains Neutral Rating MT
Big tech saves the day
Morgan Stanley Cuts Price Target on Hologic to $82 From $86, Keeps Equalweight Rating MT
ANALYST RECOMMENDATIONS : Airbnb, Apple, Best Buy, Diageo, Tesla...
Stocks Rebound, Notching Weekly Gains MT
Risk Appetite Intact After Powell's Thursday Speech; Equities Rise Friday MT
Equity Markets Rebound Intraday MT
The market is about to call Powell's bluff
RBC Cuts Price Target on Hologic to $72 From $74, Keeps Sector Perform Rating MT
ANALYST RECOMMENDATIONS : Astrazeneca, Biogen, Meta, Netflix, Take-Two, Home Depot...
Hologic fourth-quarter sales beat estimates RE
Hologic to Seek Acquisitions CI
Transcript : Hologic, Inc., Q4 2023 Earnings Call, Nov 09, 2023 CI
Hologic's Fiscal Q4 Non-GAAP Earnings Increase While Revenue Drops; Fiscal Q1, Fiscal 2024 Outlooks Issued MT
Earnings Flash (HOLX) HOLOGIC Reports Q4 Revenue $945.3M, vs. Street Est of $939.9M MT
(HOLX) HOLOGIC Expects Fiscal Year 2024 EPS Range $3.90 - $4.10 MT
Earnings Flash (HOLX) HOLOGIC Posts Q4 EPS $0.89, vs. Street Est of $0.84 MT
(HOLX) HOLOGIC Sees Q1 EPS Range $0.92 - $0.97 MT
Hologic, Inc. announces an Equity Buyback for $500 million worth of its shares. CI
Tranche Update on Hologic, Inc.'s Equity Buyback Plan announced on September 23, 2022. CI
Hologic, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2023 CI
Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024 CI
Oil and bond yields try to find toehold RE
Hologic, Inc. authorizes a Buyback Plan. CI
Chart Hologic, Inc.
More charts
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (62.1%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (25.3%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (10.8%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (1.97%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (86.2%) and services (13.8%). Net sales are distributed geographically as follows: the United States (71.3%), Europe (18.3%), Asia/Pacific (7.4%) and other (3%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Hologic, Inc. - Nasdaq
  4. News Hologic, Inc.
  5. Hologic Says US Appeals Court Affirms 2018 Patent Infringement Ruling
-40% off Black Friday : Our subscriptions help you unlock the best investment opportunities.
Enjoy this offer